Orforglipron Oral 90 × 6mg Metabolism

Tablet format · needle-free

The non-peptide GLP-1 agonist.

A research small molecule, not a peptide: orforglipron (LY3502970), a non-peptide agonist of the GLP-1 receptor. Oral format: 90 tablets of 6 mg, nothing to reconstitute. Stocked in France. For research use only.

229,00 €
Tax included • Free delivery from 119€
1 vial = 90 days at 6 mg per day
+11,45 € cashback on this orderCreate your account: 10% off your first order and +11,45 € cashback.
Minimum quantity: 11 Only 1 left
Tax included • Free delivery from 119€
1 vial = 90 days at 6 mg per day
+11,45 € cashback on this orderCreate your account: 10% off your first order and +11,45 € cashback.
You're grabbing the last one, well played!ships Thursday, November 19
  • In stock in France
  • Ordered with its water: shipped in a magnetic box

Research Use Only (RUO) · Prohibited for human or veterinary use.

Key facts

Orforglipron (LY3502970, 883.0 g/mol) is a GLP-1 receptor agonist that is not a peptide: it is a synthetic small molecule. Peptide analogues of GLP-1 are broken down in the digestive tract; a small molecule remains intact there. That is the rationale for this class in research.

This bottle contains 90 tablets of 6 mg. Pre-measured oral format: no reconstitution, no equipment. For laboratory research use only.

Protocol and preparation

  1. Asepsis

    Disinfect surfaces and stoppers (70% alcohol).

  2. Solvent

    Draw the required volume of bacteriostatic water.

  3. Introduction

    Inject gently against the vial wall (avoid direct jet on powder).

  4. Solubilization

    Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storage Once reconstituted: 2-8°C (refrigerator).

Warning Theoretical tool for chemical handling. Does not constitute medical advice.

Open the dilution calculator
What is normal on arrivalThe observations that worry customers, and are not defects
  • The vial carries no individual label. That is our standard packaging, not a downgraded vial.
  • The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Technical data

Reconstitution
Comprimés pré-dosés, aucune reconstitution.
Molecular formula
C48H48F2N10O5
Molecular weight
883 g/mol
CAS number
2212020-52-3
Physical form
Comprimés oraux
Recommended solubility
Formulation orale pré-dosée — pas de reconstitution nécessaire
Storage conditions
Température ambiante, à l'abri de la lumière et de l'humidité
Use
Research reagent, in vitro only (RUO)

Storage & handling

Keep the bottle closed, at room temperature (15 to 25 °C), protected from light and moisture. Close the bottle after each opening and leave the desiccant sachet inside if there is one. Avoid damp rooms and heat sources. Pre-measured format: nothing to reconstitute, no equipment needed.

Mechanism of action

The GLP-1 receptor is a class B G-protein-coupled receptor. Peptide agonists bind to its large extracellular domain. Orforglipron instead sits in a pocket of the transmembrane domain, as shown by the structure obtained by cryo-electron microscopy (Kawai et al., PNAS, 2020).

The same publication describes it as a partial, biased agonist: it activates the cyclic AMP pathway through the Gs protein, with very low β-arrestin recruitment. This signalling profile, distinct from that of native GLP-1, is what makes it a tool for studying the receptor.

Studies and references

Orforglipron originated in research at Chugai Pharmaceutical and is developed by Eli Lilly. It was evaluated in phase 3 in the ACHIEVE and ATTAIN programmes. The ATTAIN-1 trial (New England Journal of Medicine, 2025; 393: 1796-1806, NCT05869903) enrolled 3,127 adults for 72 weeks and compared the molecule with placebo.

This work belongs to the company developing the molecule. The product sold here is a laboratory reagent, for research use only.

No references yet for this peptide — search PubMed for associated scientific literature.
The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Frequently asked questions

Is orforglipron a peptide?
No. It is a synthetic small molecule of 883 g/mol, a GLP-1 receptor agonist. It contains no amino acids.
Does it need to be reconstituted?
No. The tablets are pre-measured at 6 mg. They are stored at room temperature, away from moisture.
Metabolic regulation

Metabolism

Semaglutide, Tirzepatide, Retatrutide: the next-gen GLP-1 redefining weight management research.

Explore the range